Authors
Maximilian Moersdorf, Philipp Sommer, Christian Sohns
Published in
Current heart failure reports. Volume 23. Issue 1. Oct 27, 2026. Epub Oct 27, 2026.
Abstract
Heart failure (HF) and atrial fibrillation (AF) frequently coexist and mutually accelerate disease progression through complex hemodynamic, neurohormonal, and structural interactions. Although earlier rhythm-control strategies failed to demonstrate mortality benefit, largely due to limitations of antiarrhythmic drug therapy, catheter ablation has fundamentally altered the therapeutic landscape.
The CASTLE-AF trial established catheter ablation as a disease-modifying therapy in patients with AF and HF with reduced ejection fraction (HFrEF), demonstrating reductions in mortality and HF hospitalization. More recently, the CASTLE-HTx trial extended these findings to patients with end-stage HF eligible for heart transplantation (HTx) or left ventricular assist device (LVAD) therapy. Catheter ablation has demonstrated a marked reduction in mortality and the need of an urgent HTx, or LVAD implantation compared with medical therapy alone. Subsequent subanalyses further refined risk stratification and identified patient subsets deriving the greatest benefit. Therefore, catheter ablation has received a class 1 recommendation for patients with AF and HFrEF. According to recent clinical evidence supporting early rhythm control through catheter ablation in advanced HF, it leads to a paradigm shift in the management of this high-risk population: in selected patients with AF and advanced HF, clinicians should not delay referral-"Don't wait, ablate."
PMID:
42944962
Bibliographic data and abstract were imported from PubMed on 28 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0